StockData
MeiraGTx Holdings plc logo

MeiraGTx Holdings plc (MGTX) stock

MGTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 13/3064% below fair value
$8.46−0.28 (-3.20%)

Close on Nov 17, 2026Market cap $812.52MP/E 11.9Yield –

MeiraGTx ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

MeiraGTx's ebitda for the twelve months ending Jun 30, 2026 was $196.13M. For fiscal 2025 it was -$93.43M. The highest annual figure on record is -$56.03M in fiscal 2019.

Annual ebitda

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$93.43M–
FY2024Dec 31, 2024-$151.38M–
FY2023Dec 31, 2023-$123.33M–
FY2022Dec 31, 2022-$107.63M–
FY2021Dec 31, 2021-$64.89M–
FY2020Dec 31, 2020-$58.38M–
FY2019Dec 31, 2019-$56.03M–

Quarterly ebitda

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$247.25M–
Q1 FY2026Mar 31, 2026-$37.81M–
Q4 FY2025Dec 31, 2025$29.59M–
Q3 FY2025Sep 30, 2025-$42.90M–
Q2 FY2025Jun 30, 2025-$41.60M–
Q1 FY2025Mar 31, 2025-$38.52M–
Q4 FY2024Dec 31, 2024-$28.42M–
Q3 FY2024Sep 30, 2024-$36.78M–
Q2 FY2024Jun 30, 2024-$42.69M–
Q1 FY2024Mar 31, 2024-$43.50M–
Q4 FY2023Dec 31, 2023-$39.84M–
Q3 FY2023Sep 30, 2023-$29.28M–
Q2 FY2023Jun 30, 2023-$25.54M–
Q1 FY2023Mar 31, 2023-$28.67M–
Q4 FY2022Dec 31, 2022-$38.56M–
Q3 FY2022Sep 30, 2022-$20.78M–
Q2 FY2022Jun 30, 2022-$21.67M–
Q1 FY2022Mar 31, 2022-$26.62M–
Q4 FY2021Dec 31, 2021-$5.63M–
Q3 FY2021Sep 30, 2021-$20.52M–
Q2 FY2021Jun 30, 2021-$18.47M–
Q1 FY2021Mar 31, 2021-$20.27M–
Q4 FY2020Dec 31, 2020-$11.87M–
Q3 FY2020Sep 30, 2020-$7.37M–
Q2 FY2020Jun 30, 2020-$24.28M–
Q1 FY2020Mar 31, 2020-$14.86M–

More MeiraGTx figures

See a number that looks wrong?